Allison Dorval, Chief Financial Officer at Voyager Therapeutics, Inc. (VYGR), sold 3,186 shares at $7.55 ($24K) on 2021-02-11, disclosed to the SEC on 2021-02-16.
Scheduled sale ($24k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VERV | SELL | 2025-04-03 | $14K | — | Filing → |
| VERV | SELL | 2024-12-03 | $3K | — | Filing → |
| PBYI | SELL | 2024-06-17 | $37K | — | Filing → |